Surrozen (NASDAQ:SRZN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Surrozen (NASDAQ:SRZN) from a hold rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on the company. Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. William Blair started coverage on Surrozen in a report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Thursday, October 15th. Guggenheim set a $80.00 target price on Surrozen and gave the company a “buy” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $54.00 price target (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.75.

Surrozen Trading Down 0.2%

Surrozen stock traded down $0.06 during mid-day trading on Friday, reaching $31.61. The company had a trading volume of 106,709 shares, compared to its average volume of 287,504. Surrozen has a fifty-two week low of $12.31 and a fifty-two week high of $37.83. The company has a market cap of $366.99 million, a P/E ratio of -0.73 and a beta of 0.51. The business has a fifty day simple moving average of $25.90 and a 200 day simple moving average of $25.52.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Monday, November 9th. The company reported ($11.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92). Research analysts forecast that Surrozen will post -10.89 EPS for the current year.

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Surrozen by 37.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company’s stock valued at $160,000 after buying an additional 1,350 shares during the period. Global Retirement Partners LLC bought a new position in shares of Surrozen during the third quarter worth about $45,000. ADAR1 Capital Management LLC bought a new position in shares of Surrozen during the first quarter worth about $350,000. Bank of New York Mellon Corp bought a new position in shares of Surrozen during the second quarter worth about $399,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Surrozen by 117.1% in the first quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after acquiring an additional 26,500 shares during the period. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Surrozen

Investors following SRZN have been watching these headlines:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $54 price target, signaling potential upside in the analyst’s view despite reduced earnings forecasts. HC Wainwright estimates and rating
• Negative Sentiment: Surrozen priced an underwritten offering of 1,894,540 common shares at $31.67 each, raising about $60 million before expenses. The new shares dilute existing shareholders and could weigh on the stock, while providing additional funding for the company. Surrozen announces offering pricing
• Negative Sentiment: HC Wainwright lowered its projected earnings per share across several future years, including estimates of losses of $12.01 for 2026 and $5.19 for 2027. The lower forecasts underscore continued expected losses, despite the firm’s Buy rating. HC Wainwright earnings estimates

Surrozen Company Profile

Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.